Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
A normative chart for cognitive development in a genetically selected population.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fiksinski Ania M, Bearden Carrie E, Bassett Anne S, Kahn René S, Zinkstok Janneke R, Hooper Stephen R, Tempelaar Wanda, McDonald-McGinn Donna, Swillen Ann, Emanuel Beverly, Morrow Bernice, Gur Raquel, Chow Eva, van den Bree Marianne, Vermeesch Joris, Warren Stephen, Owen Michael, van Amelsvoort Therese, Eliez Stephan, Gothelf Doron, Arango Celso, Kates Wendy, Simon Tony, Murphy Kieran, Repetto Gabriela, Suner Damian Heine, Vicari Stefano, Cubells Joseph, Armando Marco, Philip Nicole, Campbell Linda, Garcia-Minaur Sixto, Schneider Maude, Shashi Vandana, 22q11DS International Consortium on Brain and Behavior, Vorstman Jacob, Breetvelt Elemi J
Аннотация
Certain pathogenic genetic variants impact neurodevelopment and cause deviations from typical cognitive trajectories. Understanding variant-specific cognitive trajectories is clinically important for informed monitoring and identifying patients at risk for comorbid conditions. Here, we demonstrate a variant-specific normative chart for cognitive development for individuals with 22q11.2 deletion syndrome (22q11DS). We used IQ data from 1365 individuals with 22q11DS to construct variant-specific normative charts for cognitive development (Full Scale, Verbal, and Performance IQ). This allowed us to calculate Z-scores for each IQ datapoint. Then, we calculated the change between first and last available IQ assessments (delta Z-IQ-scores) for each individual with longitudinal IQ data (n = 708). We subsequently investigated whether using the variant-specific IQ-Z-scores would decrease required sample size to detect an effect with schizophrenia risk, as compared to standard IQ-scores. The mean Z-IQ-scores for FSIQ, VIQ, and PIQ were close to 0, indicating that participants had IQ-scores as predicted by the normative chart. The mean delta-Z-IQ-scores were equally close to 0, demonstrating a good fit of the normative chart and indicating that, as a group, individuals with 22q11DS show a decline in IQ-scores as they grow into adulthood. Using variant-specific IQ-Z-scores resulted in 30% decrease of required sample size, as compared to the standard IQ-based approach, to detect the association between IQ-decline and schizophrenia (p < 0.01). Our findings suggest that using variant-specific normative IQ data significantly reduces required sample size in a research context, and may facilitate a more clinically informative interpretation of IQ data. This approach allows identification of individuals that deviate from their expected, variant-specific, trajectory. This group may be at increased risk for comorbid conditions, such as schizophrenia in the case of 22q11DS.